Literature DB >> 15003249

Production and purification of melanoma gp100 antigen and polyclonal antibodies.

Y Gelbart1, S Frankenburg, Y Pinchasov, S Krispel, D Eliahu, O Drize, E Morag, D Bartfeld, M Lotem, T Peretz, J Pitcovski.   

Abstract

gp100 is a melanoma-associated antigen found to carry immunogenic epitopes that can induce a CTL response against tumor cells. Production and purification of large quantities of this polypeptide may be important in the context of diagnosis and vaccinating against melanoma. To overcome the hydrophobic nature of gp100, we cloned and expressed only a part of the protein, and obtained a hydrophilic recombinant polypeptide (HR-gp100) that contained most of the immunogenic peptides. High yield was achieved in an Escherichia coli expression system. The protein was purified by AKTA Prime using anionic-columns. Polyclonal antibodies developed in chicken against HR-gp100 were efficient at detecting gp100 in melanoma cells, as determined by Western blot analysis and by immunohistochemistry. HR-gp100 can be used to develop a vaccine against melanoma. Antibodies to HR-gp100 may be used to detect tumors of melanocytic origin or to determine the level of gp100 expression in tumors prior to immunotherapy with the protein or one of its peptides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003249     DOI: 10.1016/j.pep.2003.12.006

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  4 in total

1.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

2.  A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.

Authors:  Adva Levy; Jacob Pitcovski; Shoshana Frankenburg; Orit Elias; Yael Altuvia; Hanna Margalit; Tamar Peretz; Jacob Golenser; Michal Lotem
Journal:  Cell Immunol       Date:  2008-02-13       Impact factor: 4.868

3.  Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Authors:  Galit Eisenberg; Arthur Machlenkin; Shoshana Frankenburg; Adva Mansura; Jacob Pitcovski; Eitan Yefenof; Tamar Peretz; Michal Lotem
Journal:  Cell Immunol       Date:  2010-09-18       Impact factor: 4.868

4.  CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.

Authors:  Ryan M Reyes; Chenghao Zhang; Yilun Deng; Niannian Ji; Neelam Mukherjee; Alvaro S Padron; Curtis A Clark; Robert S Svatek; Tyler J Curiel
Journal:  Oncoimmunology       Date:  2021-11-22       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.